Startups
Rezera
Develops oral NLRP3 inflammasome inhibitors intended to reduce chronic inflammation in cardiovascular and neurological diseases. Its pipeline includes ruvonoflast for peripheral artery disease and brain-penetrant trabzanoflast. The company was formerly called NodThera.
Team
Alan P. WattFounder & Chief Scientific Officer |
Alex PasteurDirector |
Chris GuiffreChief Financial Officer |
David HarrisonVP, Medicinal Chemistry |
Don NicholsonBoard Chairman |
Elisabeth BjorkDirector |
 Geoff McDonoughChief Executive Officer |
Henrijette RichterDirector |
 Jim TrenkleDirector |
Julie-Ann PentonVP, Technical Operations |
Jyothis GeorgeChief Medical Officer |
Karolina ChwalekVP, Business Development |
Kevin RaidyDirector |
Nick ClarkeChief Development Officer |
Nicola LindsayVP, Clinical Program & Portfolio Management |
Pete ThorntonVP, Translational Science |
Scott RocklageDirector |
Shawna-Gay WhiteVP, Deputy General Counsel |
Valérie ReaderVP, Scientific Operations |